Last reviewed 2026-04-23 · How we verify

MesenCure

MesenCure is a mesenchymal stem cell-based therapy designed to promote tissue regeneration and reduce inflammation through paracrine signaling.

MesenCure is a mesenchymal stem cell-based therapy designed to promote tissue regeneration and reduce inflammation through paracrine signaling. Used for Indication under investigation in Phase 3 (specific indication not publicly confirmed).

At a glance

Mechanism of action

Mesenchymal stem cells (MSCs) exert therapeutic effects by secreting bioactive factors including cytokines, growth factors, and extracellular vesicles that modulate immune responses and promote tissue repair. These cells can differentiate into multiple cell types and migrate to damaged tissues, where they reduce inflammatory responses and stimulate endogenous regenerative mechanisms. The therapy leverages the immunomodulatory and regenerative properties of MSCs to address degenerative and inflammatory conditions.

Approved indications

• Indication under investigation in Phase 3 (specific indication not publicly confirmed)

Common side effects

• Infusion-related reactions
• Infection risk
• Immune response

Key clinical trials

• Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19 (PHASE1, PHASE2)
• A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MesenCure CI brief — competitive landscape report
• MesenCure updates RSS · CI watch RSS
• BonusBio Group Ltd portfolio CI